Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet HoldingsXSWX:ZBH 72 3-Year EBITDA Growth Rate is 16.20% as of Mar. 2026, which is 149% above its 10-year median of 6.50. GuruFocus rates XSWX:ZBH with a GF Score™ of 72/100 and a GF Value™ of CHF101.14. The stock has 5 warning signs investors should review. Among 693 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 60.61% on this metric.
During the past 12 months, Zimmer Biomet Holdings's average EBITDA Per Share Growth Rate was 2.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 17.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zimmer Biomet Holdings was 43.60% per year. The lowest was -18.90% per year. And the median was 6.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Zimmer Biomet Holdings 3-Year EBITDA Growth Rate Related Terms
XSWX:ZBH vs STE, PEN, PODD: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.20% mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a 3-Year EBITDA Growth Rate of 16.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zimmer Biomet Holdings and its competitors. This is 149% above median its historical median of 6.50. According to the industry distribution chart, Zimmer Biomet Holdings ranks #273 out of 693 companies in the Medical Devices & Instruments industry, placing it in the top 39.4%.
Is Zimmer Biomet Holdings' 3-Year EBITDA Growth Rate too high?
Zimmer Biomet Holdings' current 3-Year EBITDA Growth Rate of 16.20% is 149% above median its 10-year median of 6.50. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.30. Zimmer Biomet Holdings' value of 16.20% is 95.2% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #273 out of 693 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' 3-Year EBITDA Growth Rate compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #273 out of 693 companies for 3-Year EBITDA Growth Rate. This puts Zimmer Biomet Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.30. Zimmer Biomet Holdings' value of 16.20% is 95.2% above this benchmark. While the company's 10-year median is 6.50 vs. the industry median of 8.30, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.30, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current 3-Year EBITDA Growth Rate of 16.20% is 95.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current 3-Year EBITDA Growth Rate is 16.20%, which is 149% above median its own 10-year median of 6.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current 3-Year EBITDA Growth Rate of 16.20%. The stock's GF Value™ is CHF101.14, compared to a current price of CHF77.50 — trading 23.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.20%, which is 149% above median its 10-year median of 6.50 and 95.2% above the Medical Devices & Instruments industry median of 8.30. Zimmer Biomet Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current 3-Year EBITDA Growth Rate is 16.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF77.50 is trading 23.4% below its estimated GF Value™ of CHF101.14.
Key valuation signals for XSWX:ZBH:
3-Year EBITDA Growth Rate: 16.20% (149% above median its 10-year median of 6.50)
GF Value™: CHF101.14 vs. price of CHF77.50 (23.4% below fair value)
Industry Position: 95.2% above the Medical Devices & Instruments median (#273 of 693)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
72GF Score
Get the complete analysis for XSWX:ZBH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
